ArticleEMBO reports2019

CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.

Hee-Joo Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.